Stimufend
Active Ingredient(s): Pegfilgrastim-fpgkFDA Approved: * September 1, 2022
Pharm Company: * FRESENIUS KABI USA
Category: Cancer
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.[5] It serves to stimulate the production of white blood cells (neutrophils).[5][7] Pegfilgrastim was developed by Amgen.[8] Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemo... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Stimufend 6 mg/.6ml Subcutaneous Injection, Solution
NDC: 65219-371
Labeler:
Fresenius Kabi USA, LLC
